CRL : Summary for Charles River Laboratories Inte - Yahoo Finance

U.S. Markets close in 2 hrs 36 mins

Charles River Laboratories International, Inc. (CRL)


NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
88.35-0.10 (-0.11%)
As of 1:23PM EDT. Market open.
People also watch
PRXLTECHICLRCOOCBM
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close88.45
Open88.42
Bid0.00 x
Ask0.00 x
Day's Range88.10 - 88.81
52 Week Range67.20 - 91.57
Volume72,517
Avg. Volume420,333
Market Cap4.19B
Beta0.99
PE Ratio (TTM)27.39
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals9 days ago

    Charles River Labs settles with feds over NIH billing flap

    Wilmington-based Charles River Laboratories, one of the state’s largest life science companies, has agreed to pay $1.8 million to settle allegations by U.S. prosecutors that it billed the National Institutes of Health for work on contracts that it didn't perform. The U.S. Department of Justice said late Monday that Charles River (CRL) had settled the allegations under the False Claims Act, which bars contractors from defrauding federal programs. The company hold contracts under which it provides the NIH with mice and other animals for use in lab tests, and maintains colonies of animals.

  • Associated Press10 days ago

    Company to pay $1.8M to settle claims of overbilling

    BOSTON (AP) — The U.S. Department of Justice says a Massachusetts company has agreed to pay $1.8 million to settle claims it overbilled the federal government.

  • Business Wire10 days ago

    Charles River Laboratories and Chiesi Farmaceutici SpA Announce Extension of Integrated Respiratory Drug Discovery Program

    Charles River Laboratories International, Inc. , a leading early-stage contract research organization , today announced that it has extended its longstanding, strategic, integrated drug discovery partnership with Chiesi Farmaceutici SpA in the field of respiratory disease.